World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and Continuation Treatment of Major Depressive Disorder

References

• Adli M, Berghöfer A, Linden M, Helmchen H, Müller‐Oerlinghausen B, Mackert A, Stamm T, Bauer M. Effectiveness and feasibility of a standardized stepwise drug treatment algorithm for inpatients with depressive disorders ‐ results of a two‐year observational study. J Clin Psychiatry 2002, In Press
   PubMed Web of Science ®Google Scholar
• AHCPR (Agency for Health Care Policy and Research). Depression Guidelines Panel. Depression in Primary Care: Clinical Practice Guideline No. 5. AHCPR pub. No. 93–0550, Rockville, MD 1993
   Google Scholar
• AHCPR (Agency for Health Care Policy and Research). Evidence Report on Treatment of Depression: Newer Pharma‐cotherapies. AHCPR, Evidence‐Based Practice Centers. AHCPR pub. No. 99‐E014, San Antonio Evidence‐Based Practice Center, Washington, DC 1999
   Google Scholar
• Allain H, Schuck S, Mauduit N. Depression in Parkinson's disease. BMJ 2000; 320: 1287–1288
   PubMed Web of Science ®Google Scholar
• Altar C A. Neurotrophins and depression. Trends Pharmacol Sci 1999; 20: 59–61
   PubMed Web of Science ®Google Scholar
• Altshuler L L., Cohen L, Szuba M P., Burt V K., Gitlin M, Mintz J. Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines. Am J Psychiatry 1996; 153: 592–606
   PubMed Web of Science ®Google Scholar
• Altshuler L L., Cohen L S., Moline M L., Kahn D A., Carpenter D, Docherty J P., The Expert Consensus Panel for Depression in Women. The Expert consensus guideline series: treatment of depression in women. 2001, Postgrad Med Special Report 2001 (March): 1–116
   Google Scholar
• American Academy of Child and Adolescent Psychiatry. Practice parameters for the assessment and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc Psychiatry 1998; 37: 63S–83S, Suppl
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders4th revision. American Psychiatric Press, Washington, DC 1994, (DSM‐IV)
   Google Scholar
• American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 2000; 157: 1–45, Suppl
   Web of Science ®Google Scholar
• American Psychiatric Association Task Force on Electroconvulsive Therapy. The Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training, and Privileging. AP Press, Washington, DC 1990
   Google Scholar
• Advances in Neuropsychiatry and Psychopharmacology, Vol 2: Refractory Depression, J D. Amsterdam. Raven Press, New York 1991
   Google Scholar
• Amsterdam J D., Hornig‐Rohan M. Treatment algorithms in treatment‐resistant depression. Psychiatr Clin North Am 1996; 19: 371–386
   PubMed Web of Science ®Google Scholar
• Amsterdam J D., Maislin G, Potter L. Fluoxetine efficacy in treatment resistant depression. Prog Neuropsychopharmacol Biol Psychiatry 1994; 18: 243–261
   PubMed Web of Science ®Google Scholar
• Andersen G, Vestergaard K, Lauritzen L. Effective treatment of poststroke depression with the selective serotonin reuptake inhibitor citalopram. Stroke 1994; 25: 1099–1104
   PubMed Web of Science ®Google Scholar
• Anderson I M. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta‐analysis of efficacy and tolerability. J Affect Disord 2000; 58: 19–36
   PubMed Web of Science ®Google Scholar
• Anderson I M. Meta‐analytical studies on new anti‐depressants. Br Med Bull 2001; 57: 161–178
   PubMed Web of Science ®Google Scholar
• Anderson I M., Nutt D J., Deakin J F. Evidence‐based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. British Association for Psychopharmacology. J Psychopharmacol 2000; 14: 3–20
   PubMed Web of Science ®Google Scholar
• Angst J. The course of affective disorders. Psychopathology 1986; 19(Suppl 2)47–52
   PubMed Web of Science ®Google Scholar
• Angst J. Major depression in 1998: are we providing optimal therapy?. J Clin Psychiatry 1999a; 60(Suppl 6)5–9
   PubMed Web of Science ®Google Scholar
• Angst J. Suicide risk in patients with major depressive disorder. J Clin Psychiatry 1999b; 60(Suppl 2)57–62
   PubMed Web of Science ®Google Scholar
• Angst J, Preisig M. Course of a clinical cohort of unipolar, bipolar and schizoaffective patients. Results of a prospective study from 1959 to 1985. Schweiz Arch Neural Psychiatr 1995; 146: 5–16
   PubMedGoogle Scholar
• Angst J, Stabl M. Efficacy of moclobemide in different patient groups: a meta‐analysis of studies. Psychopharmacology (Berl) 1992; 106: S109–S113, Suppl
   Web of Science ®Google Scholar
• Appleby L. Suicide in psychiatric patients: risk and prevention. Br J Psychiatry 1992; 161: 749–758
   PubMed Web of Science ®Google Scholar
• Argyropoulos S V., Nutt D J. Substance P antagonists: novel agents in the treatment of depression. Expert Opin Investig Drugs 2000; 9: 1871–1875
   PubMed Web of Science ®Google Scholar
• Aronson R, Offman H J., Joffe R T., Naylor D. Triiodothyronine augmentation in the treatment of refractory depression. A meta‐analysis. Arch Gen Psychiatry 1996; 53: 842–848
   PubMed Web of Science ®Google Scholar
• Artigas F, Romero L, de Montigny C, Blier P. Acceleration of the effect of selected antidepressant drugs in major depression by 5‐HT1A antagonists. Trends Neurosci 1996; 19: 378–383
   PubMed Web of Science ®Google Scholar
• Ayuso Gutierrez J L., Alino J J. Tryptophan and an MAOI (nialamide) in the treatment of depression. A double‐blind study. Int Pharmacopsychiatry 1971; 6: 92–97
   PubMedGoogle Scholar
• Bakish D. The patient with comorbid depression and anxiety: the unmet need. J Clin Psychiatry 1999; 60(Suppl 6)20–24
   PubMed Web of Science ®Google Scholar
• Bakker A, van Balkom A J., van Dyck R. Selective serotonin reuptake inhibitors in the treatment of panic disorder and agoraphobia. Int Clin Psychopharmacol 2000; 15(Suppl 2)S25–S30
   Google Scholar
• Barbui C, Hotopf M. Amitriptyline v. the rest: still the leading antidepressant after 40 years of randomised controlled trials. Br J Psychiatry 2001; 178: 129–144
   PubMed Web of Science ®Google Scholar
• Barden N, Reul J M., Holsboer F. Do antidepressants stabilize mood through actions on the hypothalamic‐pituitary‐adreno‐cortical system?. Trends Neurosci 1995; 18: 6–11
   PubMed Web of Science ®Google Scholar
• Bauer M, Hellweg R, Cräf K J., Baumgartner A. Treatment of refractory depression with high‐dose thyroxine. Neuropsycho‐pharmacology 1998; 18: 444–455
   PubMed Web of Science ®Google Scholar
• Bauer M, Döpfmer S. Lithium augmentation in treatment‐resistant depression ‐ A meta‐analysis of placebo‐controlled studies. J Clin Psychopharmacol 1999; 19: 427–434
   PubMed Web of Science ®Google Scholar
• Bauer M, Bschor T, Kunz D, Berghöfer A, Ströhle S, Müller‐Oerlinghausen B. Double‐blind, placebo‐controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression. Am J Psychiatry 2000; 157: 1429–1435
   PubMed Web of Science ®Google Scholar
• Bauer M, Helmchen H. General principles of the treatment of depressive and manic disorders. Contemporary Psychiatry, H Helmchen, F Henn, H Lauter, N Sartorius. Springer, Heidelberg 2000; Vol. 3: 305–316
   Google Scholar
• Bauer M, Whybrow P C. Thyroid hormone, neural tissue and mood modulation. World J Biol Psychiatry 2001; 2: 57–67
   Google Scholar
• Bauer M, Whybrow P C., Angst J, Versiani M, Möller H J., WFSBP Task Force on Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, Part 2: Maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthreshold depressions. World J Biol Psychiatry.
   Google Scholar
• Baumann P. Pharmacokinetic‐pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharma‐cokinet 1996; 31: 444–469
   PubMed Web of Science ®Google Scholar
• Baumann P, Nil R, Souche A, Montaldi S, Baettig D, Lambert S, Uehlinger C, Kasas A, Amey M, Jonzier‐Perey M. A double‐blind, placebo‐controlled study of citalopram with and without lithium in the treatment of therapy‐resistant depressive patients: A clinical, pharmacokinetic, and pharmacogenetic investigation. J Clin Psychopharmacol 1996; 16: 307–314
   PubMed Web of Science ®Google Scholar
• Bech P, Rafaelsen O J. The melancholia scale: development, consistency, validity and utility. Assessment of Depression, N Sartorius, T A. Ban. Springer, Berlin; Heidelberg 1986; 259–269
   Google Scholar
• Bech P, Cialdella P, Haugh M C., Birkett M A., Hours A, Boissel J P., Tollefson C D. Meta‐analysis of randomised controlled trials of fluoxetine v. placebo and tricyclic antidepressants in the short‐term treatment of major depression. Br J Psychiatry 2000; 176: 421–428
   PubMed Web of Science ®Google Scholar
• Beck A T., Rush A J., Shaw B F., Emery C. Cognitive therapy of depression. Guilford, New York 1979
   Google Scholar
• Bellack A S., Hersen M. A comparison of social‐skills training, pharmacotherapy, and psychotherapy for depression. Behav Res Ther 1983; 21: 101–107
   PubMed Web of Science ®Google Scholar
• Benkert O, Hippius H. Kompendium der Psychiatrischen Pharmakotherapie2. überarbeitete Auflage. Springer, Berlin, Heidelberg 2000
   Google Scholar
• Berglund M, Nordström C. Mood disorders in alcoholism. Curr Opinion Psychiatry 1984; 2: 428–433
   Google Scholar
• Berman R M., Narasimhan M, Sanacora C, Miano A P., Hoffman R E., Hu X S., Charney D S., Boutros N N. A randomized clinical trial of repetitive transcranial magnetic stimulation in the treatment of major depression. Biol Psychiatry 2000; 47: 332–337
   PubMed Web of Science ®Google Scholar
• Bertilsson L, Dahl M L., Tybring C. Pharmacogenetics of antidepressants: clinical aspects. Acta Psychiatr Scand 1997; 391: 14–21, Suppl
   Google Scholar
• Bezchlibnyk‐Butler K Z., Jeffries J J. Clinical Handbook of Psychotropic Drugs. Hogrefe & Huber Publishers, Seattle 1996
   Google Scholar
• Birmaher B, Ryan N D., Williamson D E., Brent D A., Kaufman j, Dahl R E., Perel J, Nelson B. Childhood and adolescent depression: a review of the past 10 years. Part I. J Am Acad Child Adolesc Psychiatry 1996; 35: 1427–1439
   PubMed Web of Science ®Google Scholar
• Birmaher B, Brent D A., Benson R S. Summary of the practice parameters for the assessment and treatment of children and adolescents with depressive disorders. American Academy of Child and Adolescent Psychiatry. J Am Acad Child Adolesc Psychiatry 1998; 37: 1234–1238
   PubMed Web of Science ®Google Scholar
• Blackburn I M., Moore R C. Controlled acute and follow‐up trial of cognitive therapy and pharmacotherapy in out‐patients with recurrent depression. Br J Psychiatry 1997; 171: 328–334
   PubMed Web of Science ®Google Scholar
• Blumenthal J A., Babyak M A., Moore K A., Craighead W E., Herman S, Khatri P, Waugh R, Napolitano M A., Forman L M., Appelbaum M, Doraiswamy P M., Krishnan K R. Effects of exercise training on older patients with major depression. Arch Intern Med 1999; 159: 2349–2356
   PubMed Web of Science ®Google Scholar
• Blumenthal S J. Youth suicide: risk factors, assessment, and treatment of adolescent and young adult suicidal patients. Psychiatr Clin North Am 1990; 13: 511–556
   PubMed Web of Science ®Google Scholar
• Boland R J., Keller M B. Other affective disorders. Contemporary Psychiatry, H Helmchen, F Henn, H Lauter, N Sartorius. Springer, Heidelberg 2000; Vol. 3: 217–230
   Google Scholar
• Bondareff W, Alpert M, Friedhoff A J., Richter E, Clary C M., Batzar E. Comparison of sertraline and nortriptyline in the treatment of major depressive disorder in late life. Am J Psychiatry 2000; 157: 729–736
   PubMed Web of Science ®Google Scholar
• Booth B M., Zhang M, Rost K M., Clardy J A., Smith L G., Smith G R. Measuring outcomes and costs for major depression. Psychopharmacol Bull 1997; 33: 653–658
   PubMedGoogle Scholar
• Bostwick J M., Pankratz V S. Affective disorders and suicide risk: a reexamination. Am J Psychiatry 2000; 157: 1925–1932
   PubMed Web of Science ®Google Scholar
• Boukoms A, Mangini L. Pergolide: an antidepressant adjuvant for mood disorders?. Psychopharmacol Bull 1993; 29: 207–211
   PubMedGoogle Scholar
• Bourgon L N., Kellner C H. Relapse of depression after ECT: a review. J ECT 2000; 16: 19–31
   PubMed Web of Science ®Google Scholar
• Brent D A., Ryan N, Dahl R, Birmaher. Early‐onset mood disorder. Psychopharmacology: The Fourth Generation of Progress, F E. Bloom, D J. Kupfer. Raven Press, New York 1995; 1631–1642
   Google Scholar
• Brøsen K. Drug‐metabolizing enzymes and therapeutic drug monitoring in psychiatry. Ther Drug Monit 1996; 18: 393–396
   PubMed Web of Science ®Google Scholar
• Brøsen K. Differences in interactions of SSRIs. Int Clin Psychopharmacol 1998; 13(Suppl 5)S45–S47
   Web of Science ®Google Scholar
• Brunello N, Burrows C D., Jönsson C PB, Judd L L., Kasper S, Keller M B., Kupfer D J., Lecrubier Y, Mendlewicz J, Montgomery S A., Nemeroff C B., Preskom S, Racagni G, Rush A J. Critical issues in the treatment of affective disorders. Depression 1995; 3: 187–198
   Google Scholar
• Burrows C D., Norman T R. Treatment‐resistant unipolar depression. Difficult Clinical Problems in Psychiatry, M Lader, D Naber. Martin Dunitz Ltd, London 1999; 57–75
   Google Scholar
• Burt V K., Suri R, Altshuler L L., Stowe Z N., Hendrick V, Muntean E. The use of psychotropic medications during breast‐feeding. Am J Psychiatry 2001; 158: 1001–1009
   PubMed Web of Science ®Google Scholar
• Byerley W F., Judd L L., Relmherr F W., Grosser B I. 5‐Hydroxytryptophan: a review of its antidepressant efficacy and adverse effects. J Clin Psychopharmacol 1987; 7: 127–137
   PubMed Web of Science ®Google Scholar
• CANMAT (Canadian Psychiatric Association and the Canadian Network for Mood and Anxiety Treatments). Clinical Guidelines for the Treatment of Depressive Disorders. Can J Psychiatry 2000; 46(Suppl 1)1S–90S
   Google Scholar
• Carpenter L L., Jocic Z, Hall J M., Rasmussen S A., Price L H. Mirtazapine augmentation in the treatment of refractory depression. J Clin Psychiatry 1999; 60: 45–49
   PubMed Web of Science ®Google Scholar
• Chambers C D., Johnson K A., Dick L M., Felix R J., Jones K L. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996; 335: 1010–1015
   PubMed Web of Science ®Google Scholar
• Chiba K, Kobayashi K. Antidepressants. Metabolic Drug Interactions, R H. Levy, K E. Thummel, W F. Trager, P D. Hansten, M Eichelbaum. Lippincott Williams & Wilkins, Philadelphia 2000; 233–243
   Google Scholar
• Cole M C., Bellavance F, Asmaaˇ M. Prognosis of depression in elderly community and primary care populations: a systematic review and meta‐analysis. Am J Psychiatry 1999; 156: 1182–1189
   PubMed Web of Science ®Google Scholar
• Coppen A, Shaw D M., Farrell J P. Potentiation of anti‐depressive effect of a monoamine‐oxidase inhibitor by tryptophan. Lancet 1963; 1: 79–81
   PubMed Web of Science ®Google Scholar
• Coppen A, Shaw D M., Herzberg B, Maggs R. Tryptophan in the treatment of depression. 1967; 2: 1178–1180
   Google Scholar
• Coryell W. Augmentation strategies for inadequate antidepressant response: a review of placebo‐controlled studies. Ann Clin Psychiatry 2000; 12: 141–146
   PubMedGoogle Scholar
• Crismon M L., Trivedi M, Pigott T A., Rush A J., Hirschfeld R M., Kahn D A., DeBattista C, Nelson J C., Nierenberg A A., Sackeim H A., Thase M E. The Texas Medication Algorithm Project: report of the Texas Consensus Conference Panel on Medication Treatment of Major Depressive Disorder. J Clin Psychiatry 1999; 60: 142–156
   PubMed Web of Science ®Google Scholar
• Dam J, Ryde L, Svejso J, Lauge N, Lauritsen B, Bech P. Morning fluoxetine plus evening mianserin versus morning fluoxetine plus evening placebo in the acute treatment of major depression. Pharmacopsychiatry 1998; 31: 48–54
   PubMed Web of Science ®Google Scholar
• Danish University Antidepressant Group. Citalopram: clinical effect profile in comparison with clomipramine. A controlled multi‐center study. Psychopharmacology (Berl) 1986; 90: 131–138
   PubMed Web of Science ®Google Scholar
• Danish University Antidepressant Group. Modobemide: a reversible MAO‐A‐inhibitor showing weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord 1993; 28: 105–116
   PubMed Web of Science ®Google Scholar
• Danish University Antidepressant Group. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord 1999; 18: 289–299
   Google Scholar
• Datto C J. Side effects of electroconvulsive therapy. Depress Anxiety 2000; 12: 130–134
   PubMed Web of Science ®Google Scholar
• Davidson J R. Pharmacotherapy of generalized anxiety disorder. J Clin Psychiatry 2001; 62(Suppl 11)46–50
   PubMedGoogle Scholar
• De jonghe F, Kool S, van Aalst G, Dekker J, Peen J. Combining psychotherapy and antidepressants in the treatment of depression. J Affect Disord 2001; 64: 217–229
   PubMed Web of Science ®Google Scholar
• DeRubeis R J., Gerfand L A., Tang T Z., Simons A D. Medications versus cognitive behavior therapy for severely depressed outpatients: mega‐analysis of four randomized comparisons. Am J Psychiatry 1999; 156: 1007–1013
   PubMed Web of Science ®Google Scholar
• Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde, DGPPN. Praxisleitlinien in Psychiatrie und Psychotherapie (Gaebel W, Falkai P, Redaktion). Behand‐lungsleitlinie Affektfve Erkrankungen, Steinkopff, Darmstadt 2000; Band 5
   Google Scholar
• Devanand D P., Dwork A J., Hutchinson E R., Bolwig T G., Sackeim H A. Does ECT alter brain structure?. Am J Psychiatry 1994; 151: 957–970
   PubMed Web of Science ®Google Scholar
• Devanand D P., Sano M, Tang M X., Taylor S, Gurland B J., Wilder D, Stem Y, Mayeux R. Depressed mood and the incidence of Alzheimer's disease in the elderly living in the community. Arch Gen Psychiatry 1996; 53: 175–182
   PubMed Web of Science ®Google Scholar
• Dietrich D E., Emrich H M. The use of anticonvulsants to augment antidepressant medication. J Clin Psychiatry 1998; 59(Suppl 5)51–58
   PubMed Web of Science ®Google Scholar
• DiMatteo M R., Lepper H S., Crogan T W. Depression is a risk factor for noncompliance with medical treatment: meta‐analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 2000; 160: 2001–2007
   Google Scholar
• Dimeo F, Bauer M, varahram I, Proest G, Halter U. Benefits from aerobic exercise in patients with major depression: a pilot study. Brit J Sports Med 2001; 35: 114–117
   PubMed Web of Science ®Google Scholar
• Dobson K S. A metaanalysis of the efficacy of cognitive therapy for depression. J Consult Clin Psychol 1989; 57: 414–419
   PubMed Web of Science ®Google Scholar
• Duman R S., Heninger G R., Nestler E J. A molecular and cellular theory of depression. Arch Gen Psychiatry 1997; 54: 607–608
   PubMed Web of Science ®Google Scholar
• Duman R S. Novel therapeutic approaches beyond the serotonin receptor. Biol Psychiatry 1998; 44: 324–335
   PubMed Web of Science ®Google Scholar
• Dunner D L., Cohn J B., Walshe T, 3rd, Cohn C K., Feighner J P., Fieve R R., Halikas J P., Hartford J T., Hearst E D., Settle E C., Jr. Two combined, multicenter double‐blind studies of paroxetine and doxepine in geriatric patients with major depression. J Clin Psychiatry 1992; 53: 57–60, Suppl
   PubMed Web of Science ®Google Scholar
• Eastman C I., Young M A., Fogg L F., Liu L, Meaden P M. Bright light treatment of winter depression: a placebo‐controlled trial. Arch Gen Psychiatry 1998; 55: 883–889
   PubMed Web of Science ®Google Scholar
• Edwards J G., Anderson I. Systematic review and guide to selection of selective serotonin reuptake inhibitors. Drugs 1999; 57: 507–533
   PubMed Web of Science ®Google Scholar
• Einarson T R., Arikian S R., Casciano J, Doyle J J. Comparison of extended‐release venlafaxine, selective serotonin reuptake inhibitors, and tricyclic antidepressants in the treatment of depression: a meta‐analysis of randomized controlled trials. Clin Ther 1999; 21: 296–308
   PubMed Web of Science ®Google Scholar
• Elkin I, Shea M T., Watkins J T., Imber S D., Sotsky S M., Collins J F., Glass D R., Pilkonis P A., Leber W R., Docherty J P., Fiester S J., Parloff M B. NIMH Treatment of Depression Collaborative Research Program: general effectiveness of treatments. Arch Gen Psychiatry 1989; 46: 971–982
   PubMed Web of Science ®Google Scholar
• Emslie G J., Rush A J., Weinberg W A., Kowatch R A., Hughes C W., Carmody T, Rintelmann J. A double‐blind, randomized, placebo‐controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry 1997; 54: 1031–1037
   PubMed Web of Science ®Google Scholar
• Enns M W., Swenson J R., McLntyre R S., Swinson R P., Kennedy S H. Clinical guidelines for the treatment of depressive disorders. VII. Comorbidity. Can J Psychiatry 2001; 46(Suppl 1)77S–90S
   PubMed Web of Science ®Google Scholar
• Entsuah A R., Rudolph R L., Chitra R. Effectiveness of venlafaxine treatment in a broad spectrum of depressed patients: a meta‐analysis. Psychopharmacol Bull 1995; 31: 759–766
   PubMedGoogle Scholar
• Fava G A., Rafanelli C, Grandi S, Conti S, Belluardo P. Prevention of recurrent depression with cognitive behavioral therapy: preliminary findings. Arch Gen Psychiatry 1998; 55: 816–820
   PubMed Web of Science ®Google Scholar
• Fava M, Kendler K S. Major depressive disorder. Neuron 2000; 28: 335–341
   PubMed Web of Science ®Google Scholar
• Fawcett J, Barkin R L. A meta‐analysis of eight randomized, double‐blind, controlled clinical trials of mirtazapine for the treatment of patients with major depression and symptoms of anxiety. J Clin Psychiatry 1998; 59: 123–127
   PubMed Web of Science ®Google Scholar
• Feighner J P. Mechanism of action of antidepressant medications. J Clin Psychiatry 1999; 60(Suppl 4)4–11
   PubMed Web of Science ®Google Scholar
• Ferguson J M. The effects of antidepressants on sexual functioning in depressed patients: a review. J Clin Psychiatry 2001; 62(Suppl 3)22–34
   PubMed Web of Science ®Google Scholar
• Ferreri M, Lavergne F, Berlin I, Payan C, Puech A J. Benefits from mianserin augmentation of fluoxetine in patients with major depression non‐responders to fluoxetine alone. Acta Psychiatr Scand 2001; 103: 66–72
   PubMed Web of Science ®Google Scholar
• Fink M. Convulsive therapy: a review of the first 55 years. J Affect Disord 2001; 63: 1–15
   PubMed Web of Science ®Google Scholar
• Fleming J E., Offord D R. Epidemiology of childhood depressive disorders: a critical review. J Am Acad Child Adolesc Psychiatry 1990; 29: 571–580
   PubMed Web of Science ®Google Scholar
• Flint A J. Choosing appropriate antidepressant therapy in the elderly. A risk‐benefit assessment of available agents. Drugs Aging 1998; 13: 269–280
   PubMed Web of Science ®Google Scholar
• Flint A J., Rifat S L. The treatment of psychotic depression in later life: a comparison of pharmacotherapy and ECT. Int J Geriatr Psychiatry 1998; 13: 23–28
   PubMed Web of Science ®Google Scholar
• Frank E, Kupfer D J. Axis II personality disorders and personality features in treatment‐resistant and refractory depression. Treatment Strategies for Refractory Depression, S P. Roose, A H. Classman. American Psychiatric Press, Washington, DC 1990; 207–221
   Google Scholar
• Frank E, Prien R F., Jarrett R B., Keller M B., Kupfer D J., Lavori P W., Rush A J., Weissmann M M. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Arch Gen Psychiatry 1991; 48: 851–855
   PubMed Web of Science ®Google Scholar
• Frank E, Thase M E., Spanier C, Cyranowski J M., Siegel L. Psychotherapy of affective disorders. Contemporary Psychiatry, H Helmchen, F Henn, H Lauter, N Sartorius. Springer, Heidelberg 2000; Vol. 3: 348–363
   Google Scholar
• Furukawa T, Streiner D L., Young L T. Antidepressant plus benzodiazepine for major depression (Cochrane Review). The Cochrane Library, Issue 1. Update Software, Oxford 2001
   Google Scholar
• Gaffan E A., Tsaousis I, Kemp‐Wheeler S M. Researcher allegiance and meta‐analysis: the case of cognitive therapy for depression. J Consult Clin Psychol 1995; 63: 966–980
   PubMed Web of Science ®Google Scholar
• Gagné C C., Jr, Furman M J., Carpenter L L., Price L H. Efficacy of continuation ECT and antidepressant drugs compared to long‐term antidepressants alone in depressed patients. Am J Psychiatry 2000; 157: 1960–1965
   PubMed Web of Science ®Google Scholar
• Geddes J R., Freemantle N, Mason J, Eccles M P., Boynton J. Selective serotonin reuptake inhibitors (SSRIs) for depression (Cochrane Review). The Cochrane Library, Issue 3. Update Software, Oxford 2001
   Google Scholar
• Geller B, Reising D, Leonard H L., Riddle M A., Walsh B T. Critical review of tricyclic antidepressant use in children and adolescents. J Am Acad Child Adolesc Psychiatry 1999; 38: 513–516
   PubMed Web of Science ®Google Scholar
• George M S., Wassermann E M., Kimbrell T A., Little J T., Williams W E., Danielson A L., Greenberg B D., Hallett M, Post R M. Mood improvement following daily left prefrontal repetitive transcranial magnetic stimulation in patients with depression: a placebo‐controlled crossover trial. Am J Psychiatry 1997; 154: 1752–1756
   PubMed Web of Science ®Google Scholar
• George M S., Lisanby S H., Sackeim H A. Transcranial magnetic stimulation: applications in neuropsychiatry. Arch Gen Psychiatry 1999; 56: 300–311
   PubMed Web of Science ®Google Scholar
• George M S., Sackeim H A., Rush A J., Marangell L B., Nahas Z, Husain M M., Lisanby S, Burt T, Goldman J, Ballenger J C. Vagus nerve stimulation: a new tool for brain research and therapy. Biol Psychiatry 2000; 47: 287–295
   PubMed Web of Science ®Google Scholar
• Gerson S, Belin T R., Kaufman A, Mintz J, Jarvik L. Pharmacological and psychological treatments for depressed older patients: a meta‐analysis and overview of recent findings. Harv Rev Psychiatry 1999; 7: 1–28
   PubMed Web of Science ®Google Scholar
• Gilbert D A., Altshuler K Z., Rago W V., Shon S P., Crismon M L., Toprac M G., Rush A J. Texas medication algorithm project: definitions, rationale, and methods to develop medication algorithms. J Clin Psychiatry 1998; 59: 345–351
   PubMed Web of Science ®Google Scholar
• Gill D, Hatcher S. Antidepressants for depression in people with physical illness (Cochrane Review). The Cochrane Library, Issue 1. Update Software, Oxford 2001
   Google Scholar
• Glassman A H., Platman S R. Potentiation of a monoamine oxidase inhibitor by tryptophan. J Psychiatr Res 1969; 7: 83–88
   PubMed Web of Science ®Google Scholar
• Glogauen V, Cottraux J, Cucherat M, Blackburn I M. A metaanalysis of the effects of cognitive therapy in depressed patients. J Affect Disord 1998; 49: 59–72
   PubMed Web of Science ®Google Scholar
• Goodnick P J., Jorge C A., Hunter T, Kumar A M. Nefazodone treatment of adolescent depression: an open‐label study of response and biochemistry. Ann Clin Psychiatry 2000; 12: 97–100
   PubMedGoogle Scholar
• Greenberg P E., Stiglin L E., Finkelstein S N., Berndt E R. The economic burden of depression in 1990. J Clin Psychiatry 1993; 54: 405–418
   PubMed Web of Science ®Google Scholar
• Guscott R, Grof P. The clinical meaning of refractory depression: a review for the clinician. Am J Psychiatry 1991; 148: 695–704
   PubMed Web of Science ®Google Scholar
• Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76–338, National Institute of Mental Health, Rockville, MD 1976; 218–222
   Google Scholar
• Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56–62
   PubMed Web of Science ®Google Scholar
• Harrington R, Whittaker J, Shoebridge P. Psychological treatment of depression in children and adolescents. A review of treatment research. Br J Psychiatry 1998; 173: 291–298
   PubMed Web of Science ®Google Scholar
• Hawley C J., Pattinson H A., Quick S J., Echlin D, Smith V, McPhee S, Sivakumaran T. A protocol for the pharmacologic treatment of major depression. A field test of a potential prototype. J Affect Disord 1998; 47: 87–96
   PubMed Web of Science ®Google Scholar
• Hazell P, O'Connell D, Heathcote D, Henry D. Tricyclics in child and adolescent depression (Cochrane Review). The Cochrane Library, Issue 3. Update Software, Oxford 2001
   Google Scholar
• Hendrick V, Fukuchi A, Altshuler L L., Widawsky M, Wertheimer A, Brunhuber M. Use of sertraline, paroxetine and fluvoxamine by nursing women. Br J Psychiatry 2001; 179: 163–166
   PubMed Web of Science ®Google Scholar
• Hiemke C, Härtter S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther 2000; 85: 11–28
   PubMed Web of Science ®Google Scholar
• Hirschfeld R M., Montgomery S A., Keller M B., Kasper S, Schatzberg A F., Möller H J., Healy D, Baldwin D, Humble M, Versiani M, Montenegro R, Bourgeois M. Social functioning in depression: a review. J Clin Psychiatry 2000; 61: 268–275
   PubMed Web of Science ®Google Scholar
• Hirschfeld R M. Clinical importance of Ion‐term antidepressant treatment. Br J Psychiatry 2001; 179(Suppl 42)s4–s8
   PubMedGoogle Scholar
• Hoffbrand S, Howard L, Crawley H. Antidepressant treatment for post‐natal depression (Cochrane Review). The Cochrane Library, Issue 3. Update Software, Oxford 2001
   Google Scholar
• Hollon S D., DeRubeis R J., Evans M D., Wiener M J., Garvey M J., Grove W M., Tuason V B. Cognitive therapy and pharmacotherapy for depression. Arch Gen Psychiatry 1992; 49: 774–781
   PubMed Web of Science ®Google Scholar
• Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 2000; 23: 477–501
   PubMed Web of Science ®Google Scholar
• Holsboer F. Stress, hypercortisolism and corticosteroid receptors in depression: implications for therapy. J Affect Disord 2001; 62: 77–91
   PubMed Web of Science ®Google Scholar
• Hotopf M, Hardy R, Lewis G. Discontinuation rates of SSRIs and tricyclic antidepressants: a meta‐analysis and investigation of heterogeneity. Br J Psychiatry 1997; 170: 120–127
   PubMed Web of Science ®Google Scholar
• Inoue T, Tsuchiya K, Miura J, Sakakibara S, Denda K, Kasahara T, Koyama T. Bromocriptine treatment of tricydic and hetero‐cyclic antidepressant‐resistant depression. Biol Psychiatry 1996; 40: 151–153
   PubMed Web of Science ®Google Scholar
• Jarrett R B., Rush A J. Short term psychotherapy of depressive disorders: current status and future directions. Psychiatry 1994; 57: 115–132
   PubMed Web of Science ®Google Scholar
• Jarrett R B., Kraft D, Doyle J, Foster B M., Eaves C G., Silver P C. Preventing recurrent depression using cognitive therapy with and without a continuation phase: a randomized clinical trial. Arch Gen Psychiatry 2001; 58: 381–388
   PubMed Web of Science ®Google Scholar
• Joffe R T., Singer W, Levitt A J., MacDonald C. A placebo‐controlled comparison of lithium and triiodothyronine augmentation of tricydic antidepressants in unipolar refractory depression. Arch Cen Psychiatry 1993; 50: 387–393
   PubMed Web of Science ®Google Scholar
• Judd L L., Akiskal H S., Maser J D., Zeller P J., Endicott J, Coryell W, Paulus M P., Kunovac J L., Leon A C., Mueller T I., Rice J A., Keller M B. A prospective 12‐year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. Arch Cen Psychiatry 1998; 55: 694–700
   PubMed Web of Science ®Google Scholar
• Judd L L., Akiskal H S., Zeller P J., Paulus M, Leon A C., Maser J D., Endicott J, Coryell W, Kunovac J L., Mueller T I., Rice J P., Keller M B. Psychosocial disability during the long‐term course of unipolar major depressive disorder. Arch Cen Psychiatry 2000a; 57: 375–380
   PubMed Web of Science ®Google Scholar
• Judd L L., Paulus M J., Schettler P J., Akiskal H S., Endicott J, Leon A C., Maser J D., Mueller T, Solomon D A., Keller M B. Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness?. Am J Psychiatry 2000b; 157: 1501–1504
   PubMed Web of Science ®Google Scholar
• Karlsson I, Codderis J, Augusto De Mendonca Lima C, Nygaard H, Simanyi M, Taal M, Eglin M. A randomised, double‐blind comparison of the efficacy and safety of citalopram compared to mianserin in elderly, depressed patients with or without mild to moderate dementia. Int J Ceriatr Psychiatry 2000; 15: 295–305
   PubMed Web of Science ®Google Scholar
• Kasper S. Efficacy of antidepressants in the treatment of severe depression: the place of mirtazapine. J Clin Psychopharmacol 1997; 17(Suppl 1)19S–28S
   Google Scholar
• Kasper S, Wehr T A., Bartko J J., Caist P A., Rosenthal N E. Epidemiological findings of seasonal changes in mood and behavior. A telephone survey of Montgomery County, Maryland. Arch Cen Psychiatry 1989; 46: 823–833
   PubMed Web of Science ®Google Scholar
• Katon W, von Korff M, Lin E, Walker E, Simon G E., Bush T, Robinson P, Russo J. Collaborative management to achieve treatment guidelines. Impact on depression in primary care. JAMA 1995; 273: 1026–1031
   PubMed Web of Science ®Google Scholar
• Katona C L. Managing depression and anxiety in the elderly patient. Eur Neuropsychopharmacol 2000; 10(Suppl 4)S427–S432
   Web of Science ®Google Scholar
• Katona C L., Finch E JL. Lithium augmentation for refractory depression in old age. Advances in Neuropsychiatry and Psychopharmacology, Vol 2: Refractory Depression, J D. Amsterdam. Raven Press, New York 1991; 177–184
   Google Scholar
• Katona C L., Abou‐Saleh M T., Harrison D A., Nairac B A., Edwards D RL, Lock T, Bums R A., Robertson M M. Placebo‐controlled trial of lithium augmentation of fluoxetine and lofepramine. Br J Psychiatry 1995; 166: 80–86
   PubMed Web of Science ®Google Scholar
• Katona C L., Hunter B N., Bray J. A double‐blind comparison of the efficacy and safely of paroxetine and imipramine in the treatment of depression with dementia. Int J Ceriatr Psychiatry 1998; 13: 100–108
   PubMed Web of Science ®Google Scholar
• Katona C L., Bercoff E, Chiu E, Tack P, Versiani M, Woelk H. Reboxetine versus imipramine in the treatment of elderly patients with depressive disorders: a double‐blind randomised trial. J Affect Disord 1999; 55: 203–213
   PubMed Web of Science ®Google Scholar
• Keller M B., Lavori P W., Rice J, Coryell W, Hirschfeld R MA. The persistent risk of chronicity in recurrent episodes of nonbipolar major depressive disorder a prospective follow‐up. Am J Psychiatry 1986; 143: 24–28
   PubMed Web of Science ®Google Scholar
• Keller M B., McCullough J P., Klein D N., Amow B, Dunner D L., Celenberg A J., Markowitz J C., Nemeroff C B., Russell J M., Thase M E., Trivedi M H., Zajecka J. A comparison of nefazodone, the cognitive behavioral‐analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl] Med 2000; 342: 1462–1470
   PubMed Web of Science ®Google Scholar
• Keller M B., Ryan N D., Strober M, Klein R C., Kutcher S P., Birmaher B, Hagino O R., Koplewicz H, Carlson G A., Clarke C N., Emslie G J., Feinberg D, Celler B, Kusumakar V, Papatheodorou G, Sack W H., Sweeney M, Wagner K D., Weller E B., Winters N C., Oakes R, McCafferty J P. Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry 2001; 40: 762–772
   PubMed Web of Science ®Google Scholar
• Kennedy S H., Lam R W., Cohen N L., Ravindran A V., CANMAT Depression Work Group. Clinical guidelines for the treatment of depressive disorders. IV. Medications and other biological treatments. Can J Psychiatry 2001; 46(Suppl 1)38S–58S
   Google Scholar
• Kent J M. SNaRls, NaSSAs, and NaRls: new agents for the treatment of depression. Lancet 2000; 355: 911–918
   PubMed Web of Science ®Google Scholar
• Kessler R C., McGonagle K A., Zhao S, Nelson C B., Hughes M, Eshleman S, Wittchen H U., Kendler K S. Lifetime and 12‐month prevalence of DSM‐lli‐R psychiatric disorders in the United States. Arch Gen Psychiatry 1994; 51: 8–19
   PubMed Web of Science ®Google Scholar
• Kessler R C., Avenevoli S, Ries Merikangas K. Mood disorders in children and adolescents: an epidemiologic perspective. Biol Psychiatry 2001; 49: 1002–1014
   PubMed Web of Science ®Google Scholar
• Khan A, Warner H A., Brown W A. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the Food and Drug Administration database. Arch Cen Psychiatry 2000; 57: 311–317
   PubMed Web of Science ®Google Scholar
• Kim H L., Streltzer J, Goebert D. St John's wort for depression: a meta‐analysis of well‐defined clinical trials. J Nerv Ment Dis 1999; 187: 532–538
   PubMed Web of Science ®Google Scholar
• Klein E, Kreinin I, Chistyakov A, Koren D, Mecz L, Marmur S, Ben‐Shachar D, Feinsod M. Therapeutic efficacy of right pre‐frontal slow repetitive transcranial magnetic stimulation in major depression: a double‐blind controlled study. Arch Gen Psychiatry 1999; 56: 315–320
   PubMed Web of Science ®Google Scholar
• Klerman G L., Weissmann M M., Rounsaville B J., Chevron E S. Interpersonal psychotherapy of depression. Basic Books, New York 1984
   Google Scholar
• Klerman C L., Weissman M M. The course, morbidity, and costs of depression. Arch Cen Psychiatry 1992; 49: 831–834
   PubMed Web of Science ®Google Scholar
• Koran L M., Celenberg A J., Kornstein S G., Howland R H., Friedman R A., DeBattista C, Klein D, Kocsis J H., Schatzberg A F., Thase M E., Rush A J., Hirschfeld R M., LaVange L M., Keller M B. Sertraline versus imipramine to prevent relapse in chronic depression. J Affect Disord 2001; 65: 27–36
   PubMed Web of Science ®Google Scholar
• Kovacs M. Presentation and course of major depressive disorder during childhood and later years of the life span. J Am Acad Child Adolesc Psychiatry 1996; 35: 705–715
   PubMed Web of Science ®Google Scholar
• Kramer M S., Cutler N, Feighner J, Shrivastava R, Carman J, Sramek J J., Reines S A., Liu G, Snavely D, Wyatt‐Knowles E, Hale J J., Mills S G., MacCoss M, Swain C J., Harrison T, Hill R G., Hefti F, Scolnick E M., Cascieri M A., Chicchi G G., Sadowski S, Williams A R., Hewson L, Smith D, Carlson E J., Hargreaves R J., Rupniak N MJ. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 1998; 281: 1640–1645
   PubMed Web of Science ®Google Scholar
• Kuhs H, Tölle R. Sleep deprivation therapy. Biol Psychiatry 1991; 29: 1129–1148
   PubMed Web of Science ®Google Scholar
• Kuhs H, Farber D, Borgstadt S, Mrosek S, Tolle R. Amitriptyline in combination with repeated late sleep deprivation versus amitriptyline alone in major depression. A randomised study. J Affect Disord 1996; 37: 31–41
   PubMed Web of Science ®Google Scholar
• Kupfer D J. Managment of recurrent depression. J Clin Psychiatry 1993; 54(Suppl 2)29–33
   PubMed Web of Science ®Google Scholar
• Kushnir S L. Lithium‐antidepressant combinations in the treatment of depressed, physically ill geriatric patients. Am J Psychiatry 1986; 143: 378–379
   PubMed Web of Science ®Google Scholar
• Lam R W., Gorman C P., Michalon M, Steiner M, Levitt A J., Corral M R., Watson C D., Morehouse R L., Tarn W, Joffe R T. Multicenter, placebo‐controlled study of fluoxetine in seasonal affective disorder. Am J Psychiatry 1995; 152: 1765–1770
   PubMed Web of Science ®Google Scholar
• Canadian Consensus Guidelines for the Treatment of Seasonal Affective Disorder, R W. Lam, A J. Levitt. Clinical & Academic Publishing, Vancouver, BCCanada 1999
   Google Scholar
• Landén M, Björling G, Ågren H, Fahlén T. A randomized, double‐blind, placebo‐controlled trial of buspirone in combination with an SSRI in patients with treatment‐refractory depression. J Clin Psychiatry 1998; 59: 664–668
   PubMed Web of Science ®Google Scholar
• Lauritzen L, Odgaard K, Clemmesen L, Lunde M, Ohrstrom J, Black C, Bech P. Relapse prevention by means of paroxetine in ECT‐treated patients with major depression: a comparison with imipramine and placebo in medium‐term continuation therapy. Acta Psychiatr Scand 1996; 94: 241–251
   PubMed Web of Science ®Google Scholar
• Lawlor D A., Hopker S W. The effectiveness of exercise as an intervention in the management of depression: systematic review and meta‐regression analysis of randomised controlled trials. BMJ 2001; 322: 763–767
   PubMed Web of Science ®Google Scholar
• Lee T M., Chan C C. Dose‐response relationship of phototherapy for seasonal affective disorder: a meta‐analysis. Acta Psychiatr Scand 1999; 99: 315–323
   PubMed Web of Science ®Google Scholar
• Leonard B E. Mechanisms of action of antidepressants. CNS Drugs 1995; 4(Suppl 1)1–12
   Google Scholar
• Leonard H L., March J, Rickler K C., Allen A J. Pharmacology of the selective serotonin reuptake inhibitors in children and adolescents. J Am Acad Child Adolesc Psychiatry 1997; 36: 725–736
   PubMed Web of Science ®Google Scholar
• Lewinsohn P M., Clarke G. Group treatment of depressed individuals. The coping with depression course. Advances in Behavioral Research and Therapy 1984; 6: 99–114
   Web of Science ®Google Scholar
• Lewy A J., Bauer V K., Cutler N L., Sack R L., Ahmed S, Thomas K H., Blood M L., Jackson J M. Morning vs evening light treatment of patients with winter depression. Arch Gen Psychiatry 1998; 55: 890–896
   PubMed Web of Science ®Google Scholar
• Linde K, Mulrow C D. St. John's wort for depression (Cochrane Review). The Cochrane Library, 1. Update Software, Oxford 2001
   Google Scholar
• Lipsey J R., Robinson R G., Pearlson G D., Rao K, Price T R. Nortriptyline treatment of post‐stroke depression: a double‐blind study. Lancet 1984; 1: 297–300
   PubMed Web of Science ®Google Scholar
• Loo C, Mitchell P, Sachdev P, McDarmont B, Parker G, Gandevia S. Double‐blind controlled investigation of transcranial magnetic stimulation for the treatment of resistant major depression. Am J Psychiatry 1999; 156: 946–948
   PubMed Web of Science ®Google Scholar
• Lotufo‐Neto F, Trivedi M, Thase M E. Meta‐analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression. Neuropsycho‐pharmacology 1999; 20: 226–247
   PubMed Web of Science ®Google Scholar
• Løvlie R, Daly A K., Matre G E., Molven A, Steen V M. Polymorphisms in CYP2D6 duplication‐negative individuals with ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism?. Pharmacogenetics 2001; 11: 2001–2007
   Google Scholar
• Lundmark J, Bengtsson F, Nordin C, Reis M, Walinder J. Therapeutic drug monitoring of selective serotonin reuptake inhibitors influences clinical dosing strategies and reduces drug costs in depressed elderly patients. Acta Psychiatr Scand 2000; 101: 354–359
   PubMed Web of Science ®Google Scholar
• Lyketsos C G., Sheppard J M., Steele C D., Kopunek S, Steinberg M, Baker A S., Brandt J, Rabins P V. Randomized, placebo‐controlled, double‐blind clinical trial of sertraline in the treatment of depression complicating Alzheimer's disease: initial results from the Depression in Alzheimer's Disease study. Am J Psychiatry 2000; 157: 1686–1689
   PubMed Web of Science ®Google Scholar
• Mace S, Taylor D. Selective serotonin reuptake inhibitors: a review of efficacy and tolerability in depression. Expert Opin Pharmacother 2000; 1: 917–933
   PubMedGoogle Scholar
• Maes M, Vandoolaeghe E, Desnyder R. Efficacy of treatment with trazodone in combination with pindolol or fluoxetine in major depression. J Affect Disord 1996; 41: 201–210
   PubMed Web of Science ®Google Scholar
• Maier W, Schwab S, Rietschel M. Genetics of Affective Disorders. Contemporary Psychiatry, H Helmchen, F Henn, H Lauter, N Sartorius. Springer, Heidelberg 2000; Vol. 3: 243–266
   Google Scholar
• Mandoki M W., Tapia M R., Tapia M A., Sumner G S., Parker J L. Venlafaxine in the treatment of children and adolescents with major depression. Psychopharmacol Bull 1997; 33: 149–154
   PubMedGoogle Scholar
• Manly D T., Oakley S P., Jr, Bloch R M. Electroconvulsive therapy in old‐old patients. Am J Geriatr Psychiatry 2000; 8: 232–236
   PubMed Web of Science ®Google Scholar
• Maubach K A., Rupniak N M., Kramer M S., Hill R G. Novel strategies for pharmacotherapy of depression. Curr Opin Chem Biol 1999; 3: 481–488
   PubMed Web of Science ®Google Scholar
• McCullough J P. Treatment for Chronic Depression: Cognitive Behavioral Analysis System of Psychotherapy. Guilford Press, New York 2000
   Google Scholar
• McCusker J, Cole M, Keller E, Bellavance F, Berard A. Effectiveness of treatments of depression in older ambulatory patients. Arch Intern Med 1998; 158: 705–712
   PubMedGoogle Scholar
• McNamara B, Ray J L., Arthurs J, Boniface S. Transcranial magnetic stimulation for depression and other psychiatric disorders. Psychol Med 2001; 31: 1141–1146
   PubMed Web of Science ®Google Scholar
• Mendels J, Stinnett J L., Burns D, Frazer A. Amine precursors and depression. Arch Gen Psychiatry 1975; 32: 22–30
   PubMed Web of Science ®Google Scholar
• Michalets E L. Update: clinically significant cytochrome P‐450 drug interactions. Pharmacotherapy 1998; 18: 84–112
   PubMed Web of Science ®Google Scholar
• Mintz J, Mintz L I., Arruda M J., Hwang S S. Treatments of depression and functional capacity to work. Arch Gen Psychiatry 1992; 49: 761–768
   PubMed Web of Science ®Google Scholar
• Mittmann N, Herrmann N, Einarson T R., Busto U E., Lanetot K L., Liu B A., Shulman K I., Silver I L., Narango C A., Shear N H. The efficacy, safety and tolerability of antidepressants in late life depression: a meta‐analysis. J Affect Disord 1997; 46: 191–217
   PubMed Web of Science ®Google Scholar
• Möller H J. Non‐response to antidepressants: risk factors and therapeutic possibilities. Int Clin Psychopharmacol 1994; 9(Suppl 2)17–23
   PubMedGoogle Scholar
• Möller H J. Are all antidepressants the same?. J Clin Psychiatry 2000; 61(Suppl 6)24–28
   PubMed Web of Science ®Google Scholar
• Möller H J., Fuger J, Kasper S. Efficacy of new generation antidepressants: meta‐analysis of imipramine‐controlled studies. Pharmacopsychiatry 1994; 27: 215–223
   PubMed Web of Science ®Google Scholar
• Montejo A L., Llorca G, Izquierdo J A., Rico‐Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic‐Related Sexual Dysfunction. J Clin Psychiatry 2001; 62(Suppl 3)10–21
   PubMed Web of Science ®Google Scholar
• Montgomery S A., Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382–389
   PubMed Web of Science ®Google Scholar
• Montgomery S A. Selectivity of antidepressants and resistant depression. Advances in Neuropsychiatry and Psychopharmacology, Vol 2: Refractory Depression, J D. Amsterdam. Raven Press, New York 1991; 93–104
   Google Scholar
• Montgomery S A. New developments in the treatment of depression. J Clin Psychiatry 1999; 60(Suppl 14)10–15
   PubMed Web of Science ®Google Scholar
• Mueller T I., Leon A C., Keller M B., Solomon D A., Endicott J, Coryell W, Warshaw M, Maser J D. Recurrence after recovery from major depressive disorder during 15 years of observational follow‐up. Am J Psychiatry 1999; 156: 1000–1006
   PubMed Web of Science ®Google Scholar
• Mulsant B H., Pollock B G. Treatment‐resistant depression in late life. J Geriatr Psychiatry Neurol 1998; 11: 186–193
   PubMed Web of Science ®Google Scholar
• Mulsant B H., Pollock B C., Nebes R D., Miller M D., üttle J T., Stack J, Houck P R., Bensasi S, Mazumdar S, Reynolds C F., 3rd. A double‐blind randomized comparison of nortriptyline and paroxe‐tine in the treatment of late‐life depression: 6‐week outcome. J Clin Psychiatry 1999; 60(Suppl 20)16–20
   PubMedGoogle Scholar
• Murphy B E. Antiglucocorticoid therapies in major depression: a review. Psychoneuroendocrinology 1997; 22(Suppl 1)SI25–SI132
   Google Scholar
• Murray C JL, Lopez A D. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997a; 349: 1436–1342
   PubMed Web of Science ®Google Scholar
• Murray C JL, Lopez A D. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet 1997b; 349: 1498–1504
   PubMed Web of Science ®Google Scholar
• Mynors‐Wallis L M., Gath D H., Day A, Baker F. Randomised controlled trial of problem solving treatment, antidepressant medication, and combined treatment for major depression in primary care. BMJ 2000; 320: 26–30
   PubMed Web of Science ®Google Scholar
• Nelson J C. Treatment of antidepressant nonresponders: augmentation or switch?. J Clin Psychiatry 1998; 59(Suppl 15)35–41
   PubMed Web of Science ®Google Scholar
• Nelson J, Chouinard C. Guidelines for the clinical use of benzodiazepines: pharmacokinetics, dependency, rebound and withdrawal. Canadian Society for Clinical Pharmacology. Can J Clin Pharmacol 1999; 6: 69–83
   PubMedGoogle Scholar
• Nemeroff C B. Augmentation strategies in patients with refractory depression. Depress Anxiety 1996; 4: 169–181, 97
   PubMedGoogle Scholar
• Nemeroff C B. Psychopharmacology of affective disorders in the 21st century. Biol Psychiatry 1998; 44: 517–525
   PubMed Web of Science ®Google Scholar
• Nemeroff C B., Widerlov E, Bissette G, Walleus H, Karisson I, Eklund K, Kilts C D., Loosen P T., Vale W. Elevated concentrations of CSF corticotropin‐releasing factor‐like immunoreactivity in depressed patients. Science 1984; 226: 1342–1344
   PubMed Web of Science ®Google Scholar
• Nestler E J. Antidepressant treatments in the 21st century. Biol Psychiatry 1998; 44: 526–533
   PubMed Web of Science ®Google Scholar
• Newhouse P A., Krishnan K R., Doraiswamy P M., Richter E M., Batzar E D., Clary C M. A double‐blind comparison of sertraline and fluoxetine in depressed elderly outpatients. J Clin Psychiatry 2000; 61: 559–568
   PubMed Web of Science ®Google Scholar
• Nezu A M. Efficacy of social problem solving therapy for unipolar depression. J Consult Clin Psychol 1986; 54: 196–202
   PubMed Web of Science ®Google Scholar
• Nierenberg A A., Amsterdam J D. Treatment‐resistant depression: definition and treatment approaches. J Clin Psychiatry 1990; 51(Suppl 6)39–47
   PubMedGoogle Scholar
• Nierenberg A A., McLean N E., Alpert J E., Worthington J J., Rosenbaum J F., Fava M. Early nonresponse to fluoxetine as a predictor of poor 8‐week outcome. Am J Psychiatry 1995; 152: 1500–1503
   PubMed Web of Science ®Google Scholar
• Nierenberg A A., Alpert J E., Pava J, Rosenbaum J F., Fava M. Course and treatment of atypical depression. J Clin Psychiatry 1998a; 59(Suppl 18)5–9
   PubMedGoogle Scholar
• Nierenberg A A., Dougherty D, Rosenbaum J F. Dopaminergic agents and stimulants as antidepressant augmentation strategies. J Clin Psychiatry 1998b; 59(Suppl 5)60–63
   PubMedGoogle Scholar
• Nobler M S., Sackeim H A. Electroconvulsive therapy. Contemporary Psychiatry, H Helmchen, F Henn, H Lauter, N Sartorius. Springer, Heidelberg 2000; Vol. 3: 425–434
   Google Scholar
• Refractory Depression: Current Strategies and Future Directions, W A. Nolen, J Zohar, S P. Roose, J D. Amsterdam. J. Wiley & Sons, Chichester 1994
   Google Scholar
• Nordstrom P, Asberg M, Aberg‐Wistedt A, Nordin C. Attempted suicide predicts suicide risk in mood disorders. Acta Psychiatr Scand 1995a; 92: 345–350
   PubMed Web of Science ®Google Scholar
• Nordstrom P, Samuelsson M, Asberg M. Survival analysis of suicide risk after attempted suicide. Acta Psychiatr Scand 1995b; 91: 336–340
   PubMed Web of Science ®Google Scholar
• Nulman I, Koren G. The safety of fluoxetine during pregnancy and lactation. Teratology 1996; 53: 304–308
   Google Scholar
• Nulman I, Rovet J, Stewart D E., Wolpin J, Gardner H A., Theis J G., Kulin N, Koren G. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 1997; 336: 258–262
   PubMed Web of Science ®Google Scholar
• Nyth A L., Gottfries C G., Lyby K, Smedegaard‐Andersen L, Gylding‐Sabroe J, Kristensen M, Refsum H E., Ofsti E, Eriksson S, Syversen S. A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia. Acta Psychiatr Scand 1992; 86: 138–145
   PubMed Web of Science ®Google Scholar
• Old Age Depression Interest Group. How long should the elderly take antidepressants? A double‐blind placebo‐controlled study of continuation/prophylaxis therapy with dothiepin. Br J Psychiatry 1993; 162: 175–182
   PubMed Web of Science ®Google Scholar
• Ostroff R B., Nelson J C. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry 1999; 60: 256–259
   PubMed Web of Science ®Google Scholar
• Owens M J., Nemeroff C B. Corticotropin‐releasing factor antagonists in affective disorders. Expert Opin Investig Drugs 1999; 8: 1849–1858
   PubMedGoogle Scholar
• Pascual‐Leone A, Rubio B, Pallardo F, Catala M D. Rapid‐rate transcranial magnetic stimulation of left dorsolateral prefrontal cortex in drug‐resistant depression. Lancet 1996; 348: 233–237
   PubMed Web of Science ®Google Scholar
• Paykel E S. Epidemiology of refractory depression. Refractory Depression: Current Strategies and Future Directions, W A. Nolen, J Zohar, S P. Roose, J D. Amsterdam. J Wiley & Sons, Chichester 1994; 3–17
   Google Scholar
• Paykel E S., Hollyman J A., Freeling P, Sedgwick P. Predictors of therapeutic benefit from amitriptyline in mild depression: a general practice placebo‐controlled trial. J Affect Disord 1988; 14: 83–95
   PubMed Web of Science ®Google Scholar
• Paykel E S., Ramana R, Cooper Z, Hayhurst H, Kerr J, Barocka A. Residual symptoms after partial remission: an important outcome in depression. Psychol Med 1995; 25: 1171–1180
   PubMed Web of Science ®Google Scholar
• Paykel E S., Scott J, Teasdale J D., Johnson A L., Garland A, Moore R, Jenaway A, Cornwall P L., Hayhurst H, Abbott R, Pope M. Prevention of relapse in residual depression by cognitive therapy. Arch Gen Psychiatry 1999; 56: 829–835
   PubMed Web of Science ®Google Scholar
• Peretti S, Judge R, Hindmarch I. Safety and tolerability considerations: tricyclic antidepressants vs. selective serotonin reuptake inhibitors. Acta Psychiatr Scand 2000; 403(Suppl 2000)17–25
   Web of Science ®Google Scholar
• Perez V, Soler J, Puigdemont D, Alvarez E, Artigas F. A double‐blind, randomized, placebo‐controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Grup de Recerca en Trastoms Afectius. Arch Gen Psychiatry 1999; 56: 375–379
   PubMed Web of Science ®Google Scholar
• Perez‐Stable E J., Miranda J, Munoz R, Ying Y. Depression in medical outpatients: underrecognition and misdiagnosis. Arch Int Med 1990; 150: 1083–1088
   PubMed Web of Science ®Google Scholar
• Perry P J. Pharmacotherapy for major depression with melancholic features: relative efficacy of tricyclic versus selective serotonin reuptake inhibitor antidepressants. J Affect Disord 1996; 39: 1–6
   PubMed Web of Science ®Google Scholar
• Perry P J., Zeilmann C, Arndt S. Tricyclic antidepressant concentrations in plasma: an estimate of their sensitivity and specificity as a predictor of response. J Clin Psychopharmacol 1994; 14: 230–240
   PubMed Web of Science ®Google Scholar
• Petracca G, Teson A, Chemerinski E, Leiguarda R, Starkstein S E. A double‐blind placebo‐controlled study of clomipramine in depressed patients with Alzheimer's disease. J Neuropsychiatry Clin Neurosci 1996; 8: 270–275
   PubMed Web of Science ®Google Scholar
• Picinelli M, Gomez Homen F. Gender differences in the epidemiology of affective disorders and schizophrenia. World Health Organization, GenevaSwitzerland 1997
   Google Scholar
• Pigott T A., Seay S M. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive‐compulsive disorder. J Clin Psychiatry 1999; 60: 101–106
   PubMed Web of Science ®Google Scholar
• Pollock B C., Mulsant B H., Nebes R, Kirshner M A., Begley A E., Mazumdar S, Reynolds C F., 3rd. Serum anticholinergicity in elderly depressed patients treated with paroxetine or nortriptyline. Am J Psychiatry 1998; 155: 1110–1112
   PubMed Web of Science ®Google Scholar
• Potter W Z., Schmidt M E. Treatment of major depression: selection of initial drug. In: Rush AJ (ed) Mood Disorders. Systematic Medication Management. Mod Probl Pharmacopsychiatry 1997; 25: 1–16
   PubMedGoogle Scholar
• Preskorn S H. Recent pharmacologic advances in antidepres‐sant therapy for the elderly. Am J Med 1993; 94(Suppl 5A)2S–12S
   Google Scholar
• Preskorn S H., Fast C A. Therapeutic drug monitoring for anti‐depressants: efficacy, safety, and cost effectiveness. J Clin Psychiatry 1991; 52: 23–33, Suppl
   PubMed Web of Science ®Google Scholar
• Prien R F. Efficacy of continuation drug therapy of depression and anxiety: issues and methodologies. J Clin Psychopharmacol 1990; 10: 86S–90S
   Google Scholar
• Prien R F., Kupfer D J. Continuation drug therapy for major depressive episodes: How long should it be maintained?. Am J Psychiatry 1986; 143: 18–23
   PubMed Web of Science ®Google Scholar
• Quitkin F M., Harrison W, Stewart J W., McCrath P J., Tricamo E, Ocepek‐Welikson K, Rabkin J G., Wager S G., Nunes E, Klein D F. Response to phenelzine and imipramine in placebo nonresponders with atypical depression. A new application of the crossover design. Arch Gen Psychiatry 1991; 48: 319–323
   PubMed Web of Science ®Google Scholar
• Rasmussen B B., Brøsen K. Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors?. Ther Drug Monit 2000; 22: 143–154
   PubMed Web of Science ®Google Scholar
• Regier D A., Narrow W E., Rae D S., Manderscheid R W., Locke B Z., Goodwin F K. The de facto US mental and addictive disorders service system. Epidemiologic catchment area prospective 1‐year prevalence rates of disorders and services. Arch Gen Psychiatry 1993; 50: 85–94
   PubMed Web of Science ®Google Scholar
• Rehm L P. Behavior Therapy for Depression. Academic Press, New York 1979
   Google Scholar
• Reilly J G., Ayis S A., Ferrier I N., Jones S J., Thomas S H. QTc‐interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 2000; 355: 1048–1052
   PubMed Web of Science ®Google Scholar
• Reimherr F W., Amsterdam J D., Quitkin F M., Rosenbaum J F., Fava M, Zajecka J, Beasley C M., Jr, Michelson D, Roback P, Sundell K. Optimal length of continuation therapy in depression: a prospective assessment during long‐term fluoxetine treatment. Am J Psychiatry 1998; 155: 1247–1253
   PubMed Web of Science ®Google Scholar
• Reynolds C F., 3rd, Frank E, Kupfer D J., Thase M E., Perel J M., Mazumdar S, Houck P R. Treatment outcome in recurrent major depression: a post hoc comparison of elderly (“young old”) and midlife patients. Am J Psychiatry 1996; 153: 1288–1292
   PubMed Web of Science ®Google Scholar
• Reynolds C F., 3rd, Alexopoulos G S., Katz I R., Lebowitz B D. Chronic depression in the elderly: approaches for prevention. Drugs Aging 2001; 18: 507–514
   PubMed Web of Science ®Google Scholar
• Richelson E. The pharmacology of antidepressants at the synapse: focus on newer compounds. J Clin Psychiatry 1994; 55(Suppl A)34–39
   PubMed Web of Science ®Google Scholar
• Richelson E. Pharmacology of antidepressants. Mayo Clin Proc 2001; 76: 511–527
   PubMed Web of Science ®Google Scholar
• Riemann D, Konig A, Hohagen F, Kiemen A, Voderholzer U, Backhaus J, Bunz J, Wesiack B, Hermle L, Berger M. How to preserve the antidepressive effect of sleep deprivation: A comparison of sleep phase advance and sleep phase delay. Eur Arch Psychiatry Clin Neurosci 1999; 249: 231–237
   PubMed Web of Science ®Google Scholar
• Robinson R G., Schultz S K., Castillo C, Kopel T, Kosier J T., Newman R M., Curdue K, Petracca G, Starkstein S E. Nortriptyline versus fluoxetine in the treatment of depression and in short‐term recovery after stroke: a placebo‐controlled, double‐blind study. Am J Psychiatry 2000; 157: 351–359
   PubMed Web of Science ®Google Scholar
• Roose S P., Suthers K M. Antidepressant response in late‐life depression. J Clin Psychiatry 1998; 59(Suppl 10)4–8
   PubMedGoogle Scholar
• Roose S P., Laghrissi‐Thode F, Kennedy J S., Nelson J C., Bigger J T., Jr, Pollock B G., Gaffney A, Narayan M, Finkel M S., McCafferty J, Gergel I. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA 1998; 279: 287–291
   PubMed Web of Science ®Google Scholar
• Rosen L N., Targum S D., Terman M, Bryant M J., Hoffman H, Kasper S F., Hamovit J R., Docherty J P., Welch B, Rosenthal N E. Prevalence of seasonal affective disorder at four latitudes. Psychiatry Res 1990; 31: 131–144
   PubMed Web of Science ®Google Scholar
• Rosenbaum J F., Fava M, Hoog S L., Ascroft R C., Krebs W B. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry 1998; 44: 77–87
   PubMed Web of Science ®Google Scholar
• Rosenthal N E., Sack D A., Gillin J C., Lewy A J., Goodwin F K., Davenport Y, Mueller P S., Newsome D A., Wehr T A. Seasonal affective disorder. A description of the syndrome and preliminary findings with light therapy. Arch Gen Psychiatry 1984; 41: 72–80
   PubMed Web of Science ®Google Scholar
• Rothschild A J., Samson J A., Bessette M P., Carter‐Campbell J T. Efficacy of the combination of fluoxetine and perphenazine in the treatment of psychotic depression. J Clin Psychiatry 1993; 54: 338–342
   PubMed Web of Science ®Google Scholar
• Roy A, Dejong J, Lamparski D, George T, Linnoila M. Depression among alcoholics. Relationship to clinical and cerebrospinal fluid variables. Arch Gen Psychiatry 1991; 48: 428–432
   PubMed Web of Science ®Google Scholar
• Rudolph R L., Entsuah R, Chitra R. A meta‐analysis of the effects of venlafaxine on anxiety associated with depression. J Clin Psychopharmacol 1998; 18: 136–144
   PubMed Web of Science ®Google Scholar
• Ruhrmann S, Kasper S, Hawellek B, Martinez B, Hoflich G, Nickelsen T, Möller H J. Effects of fluoxetine versus bright light in the treatment of seasonal affective disorder. Psychol Med 1998; 28: 923–933
   PubMed Web of Science ®Google Scholar
• Rush A J., Crismon M L., Toprac M G., Trivedi M H., Rago W V., Shon S P., Altshuler K Z. Consensus guidelines in the treatment of major depressive disorder. J Clin Psychiatry 1998; 59(Suppl 20)73–84
   PubMedGoogle Scholar
• Rush A J., Kupfer D J. Strategies and tactics in the treatment of depression. Treatment of Psychiatric DisordersThird Edition, G O. Gabbard. American Psychiatric Publishing Inc, Washington, DC 2001; 1417–1439
   Google Scholar
• Rush A J., Thase M E. Psychotherapies for depressive disorders. WPA Series. Evidence and Experience in Psychiatry. Volume 1 — Depressive Disorders, M Maj, N Sartorius. John Wiley & Sons Ltd, ChichesterUK 1999; 161–206
   Google Scholar
• Rush A J., Rago W V., Crismon M L., Toprac M G., Shon S P., Suppes T, Miller A L., Trivedi M H., Swann A C., Biggs M M., Shores‐Wilson K, Kashner T M., Pigott J, Chiles J A., Gilbert D A., Altshuler K Z. Medication treatment for the severely and persistently ill: the Texas medication algorithm project. J Clin Psychiatry 1999; 60: 284–291
   PubMed Web of Science ®Google Scholar
• Rush A J., George M S., Sackeim H A., Marangell L B., Husain M M., Ciller C, Nahas Z, Haines S, Simpson R K., Jr, Goodman R. Vagus nerve stimulation (VNS) for treatment‐resistant depressions: a mul‐ticenter study. Biol Psychiatry 2000; 47: 276–286
   PubMed Web of Science ®Google Scholar
• Sackeim H A., Decina P, Portnoy S, Neeley P, Malitz S. Studies of dosage, seizure threshold, and seizure duration in ECT. Biol Psychiatry 1987; 22: 249–68
   PubMed Web of Science ®Google Scholar
• Sackeim H A., Prudic J, Devanand D P., Kiersky J E., Fitzsimons L, Moody B J., McElhiney M C., Coleman E A., Settembrino J M. Effects of stimulus intensity and electrode placement on the efficacy and cognitive effects of electroconvulsive therapy. N Engl J Med 1993; 328: 839–846
   PubMed Web of Science ®Google Scholar
• Sackeim H A., Haskett R F., Mulsant B H., Thase M E., Mann J J., Pettinati H M., Greenberg R M., Crowe R R., Cooper T B., Prudic J. Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial. JAMA 2001; 285: 1299–1307
   PubMed Web of Science ®Google Scholar
• Schatzberg A F. New indications for antidepressants. J Clin Psychiatry 2000; 61(Suppl 11)9–17
   PubMedGoogle Scholar
• Schuckit M A. Alcohol and depression: a clinical perspective. Acta Psychiatr Scand 1994; 377: 28–32, Suppl
   Web of Science ®Google Scholar
• Schulberg H C., Block M R., Madonia M J., Scott C P., Rodriguez E, Imber S D., Perel J, Lave J, Houck P R., Coulehan J L. Treating major depression in primary care practice: eight month clinical outcomes. Arch Cen Psychiatry 1996; 53: 913–919
   PubMed Web of Science ®Google Scholar
• Scott J. Chronic depression. Br J Psychiatry 1988; 153: 287–297
   PubMed Web of Science ®Google Scholar
• Scott J, Cilvarry E, Farrell M. Managing anxiety and depression in alcohol and drug dependence. Addict Behav 1998; 23: 919–931
   PubMed Web of Science ®Google Scholar
• Scott J, Teasdale J D., Paykel E S., Johnson A L., Abbott R, Hayhurst H, Moore R, Garland A. Effects of cognitive therapy on psychological symptoms and social functioning in residual depression. Br 1 Psychiatry 2000; 177: 440–446
   PubMed Web of Science ®Google Scholar
• Segal Z V., Kennedy S H., Cohen N L., CANMAT Depression Work Croup. Clinical guidelines for the treatment of depressive disorders. V. Combining psychotherapy and pharmaco‐therapy. Can J Psychiatry 2001; 46(Suppl 1)59S–62S
   Google Scholar
• Shaw K, Turner J, Del Mar C. Tryptophan and 5‐Hydroxytryptophan for Depression (Cochrane Review). The Cochrane Library, Issue 3. Update Software, Oxford 2001
   Google Scholar
• Shekelle P C., Woolf S H., Eccles M, Grimshaw J. Developing guidelines. BMJ 1999; 318: 593–596
   PubMed Web of Science ®Google Scholar
• Shelton R C., Keller M B., Gelenberg A, Dunner D L., Hirschfeld R, Thase M E., Russell j, Lydiard R B., Crits‐Cristoph P, Gallop R, Todd L, Hellerstein D, Goodnick P, Keitner G, Stahl S M., Halbreich U. Effectiveness of St. John's Wort in major depression. A randomized controlled trial. JAMA 2001a; 285: 1978–1986
   PubMed Web of Science ®Google Scholar
• Shelton R C., Tollefson G D., Tohen M, Stahl S, Cannon K S., Jacobs T G., Buras W R., Bymaster F P., Zhang W, Spencer K A., Feldman P D., Meltzer H Y. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001b; 158: 131–134
   PubMed Web of Science ®Google Scholar
• Sherwin B B. Estrogen and refractory depression. Advances in Neuropsychiatry and Psycho‐pharmacology, Vol 2: Refractory Depression, J D. Amsterdam. Raven Press, New York 1991; 209–218
   Google Scholar
• Shores M M., Pascualy M, Veith R C. Depression and Heart Disease: Treatment Trials. Semin Clin Neuropsychiatry 1998; 3: 87–101
   PubMedGoogle Scholar
• Simon G E., VonKorff M, Heiligenstein J H., Revicki D A., Grothaus L, Katon W, Wagner E H. Initial antidepressant choice in primary care. Effectiveness and cost of fluoxetine versus tricyclic antidepressants. JAMA 1996; 275: 1897–1902
   PubMed Web of Science ®Google Scholar
• Solomon D A., Keller M B., Leon A C., Mueller T I., Shea M T., Warshaw M, Maser J D., Coryell W, Endicott J. Recovery from major depression. A 10‐year prospective follow‐up across multiple episodes. Arch Gen Psychiatry 1997; 54: 1001–1006
   PubMed Web of Science ®Google Scholar
• Spiker D G., Weiss J C., Dealy R S., Griffin S J., Hanin I, Neil J F., Perel J M., Rossi A J., Soloff P H. The pharmacological treatment of delusional depression. Am J Psychiatry 1985; 142: 430–436
   PubMed Web of Science ®Google Scholar
• Sproule B A., Hardy B G., Shulman K I. Differential pharmaco‐kinetics of lithium in elderly patients. Drugs Aging 2000; 16: 165–177
   PubMed Web of Science ®Google Scholar
• Staab J P., Evans D L. Efficacy of venlafaxine in geriatric depression. Depress Anxiety 2000; 12(Suppl 1)63–68
   PubMed Web of Science ®Google Scholar
• Stahl S M. Placebo‐controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline. Biol Psychiatry 2000; 48: 894–901
   PubMed Web of Science ®Google Scholar
• Steffens D C., Skoog I, Norton M C., Hart A D., Tschanz J T., Plassman B L., Wyse B W., Welsh‐Bohmer K A., Breitner J C. Prevalence of depression and its treatment in an elderly population: the Cache County study. Arch Gen Psychiatry 2000; 57: 601–607
   PubMed Web of Science ®Google Scholar
• Steimer W, Muller B, Leucht S, Kissling W. Pharmacogenetics: a new diagnostic tool in the management of anti‐depressive drug therapy. Clin Chim Acta 2001; 308: 33–41
   PubMed Web of Science ®Google Scholar
• Stembach H. The serotonin syndrome. Am J Psychiatry 1995; 148: 705–713
   Google Scholar
• Storosum J G., Elferink A J., van Zwieten B J., van den Brink W, Gersons B P., van Strik R, Broekmans A W. Short‐term efficacy of tricyclic antidepressants revisited: a meta‐analytic study. Eur Neuro‐psychopharmacol 2001; 11: 173–180
   PubMed Web of Science ®Google Scholar
• Stowe Z N., Cohen L S., Hostetter A, Ritchie J C., Owens M J., Nemeroff C B. Paroxetine in human breast milk and nursing infants. Am J Psychiatry 2000; 157: 185–189
   PubMed Web of Science ®Google Scholar
• Sullivan P F., Neale M C., Kendler K S. Genetic epidemiology of major depression: review and meta‐analysis. Am J Psychiatry 2000; 157: 1552–1562
   PubMed Web of Science ®Google Scholar
• Tanaka E, Hisawa S. Clinically significant pharmacokinetic drug interactions with psychoactive drugs: antidepressants and antipsychotics and the cytochrome P450 system. J Clin Pharm Ther 1999; 24: 7–16
   PubMed Web of Science ®Google Scholar
• Taragano F E., Lyketsos C G., Mangone C A., Allegri R F., Comesana‐Diaz E. A double‐blind, randomized, fixed‐dose trial of fluoxetine vs. amitriptyline in the treatment of major depression complicating Alzheimer's disease. Psychosomatics 1997; 38: 246–252
   PubMed Web of Science ®Google Scholar
• Teri L, Reifler B V., Veith R C., Barnes R, White E, McLean P, Raskind M. Imipramine in the treatment of depressed Alzheimer's patients: impact on cognition. J Gerontol 1991; 46: P372–P377
   PubMedGoogle Scholar
• Terman M, Terman J S., Ross D C. A controlled trial of timed bright light and negative air ionization for treatment of winter depression. Arch Gen Psychiatry 1998; 55: 875–882
   PubMed Web of Science ®Google Scholar
• Tew J D., Jr, Mulsant B H., Haskett R F., Prudic J, Thase M E., Crowe R R., Dolata D, Begley A E., Reynolds C F., 3rd, Sackeim H A. Acute efficacy of ECT in the treatment of major depression in the old‐old. Am J Psychiatry 1999; 156: 1865–1870
   PubMed Web of Science ®Google Scholar
• Thase M E. Relapse and recurrence in unipolar major depression: short‐term and long‐term approaches. J Clin Psychiatry 1990; 51(Suppl 6)51–57
   PubMedGoogle Scholar
• Thase M E. Redefining antidepressant efficacy toward long‐term recovery. J Clin Psychiatry 1999; 60(Suppl 6)15–19
   PubMedGoogle Scholar
• Thase M E., Howland R H. Refractory depression: relevance of psychosocial factors and therapies. Psychiatr Ann 1994; 24: 232–240
   Web of Science ®Google Scholar
• Thase M E., Rush A J. Treatment‐resistant depression. Psychopharmacology: The Fourth Generation of Progress, F E. Bloom, D J. Kupfer. Raven Press, New York 1995; 1081–1097
   Google Scholar
• Thase M E., Rush A J. When at first you don't succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry 1997; 58(Suppl 13)23–29
   PubMed Web of Science ®Google Scholar
• Thase M E., Trivedi M H., Rush A J. MAOIs in the contemporary treatment of depression. Neuropsychopharmacology 1995; 12: 185–219
   PubMed Web of Science ®Google Scholar
• Thase M E., Greenhouse J B., Frank E, Reynolds C F., 3rd, Pilkonis P A., Hurley K, Grochocinski V, Kupfer D J. Treatment of major depression with psychotherapy or psychotherapy‐pharmaco‐therapy combinations. Arch Gen Psychiatry 1997; 54: 1009–1015
   PubMed Web of Science ®Google Scholar
• Thase M E., Howland R H., Friedman E S. Treating antidepressant nonresponders with augmentation strategies: an overview. J Clin Psychiatry 1998; 59(Suppl 5)5–12
   PubMed Web of Science ®Google Scholar
• Thase M E., Entsuah A R., Rudolph R L. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001; 178: 234–241
   PubMed Web of Science ®Google Scholar
• Thorpe L, Whitney D K., Kutcher S P., Kennedy S H., CANMAT Depression Work Group. Clinical guidelines for the treatment of depressive disorders. VI. Special populations. Can J Psychiatry 2001; 46(Suppl 1)63S–76S
   Google Scholar
• Tignol J, Stoker M J., Dunbar C C. Paroxetine in the treatment of melancholia and severe depression. Int Clin Psychopharmacol 1992; 7: 91–94
   PubMed Web of Science ®Google Scholar
• Tollefson C D., Bosomworth J C., Heiligenstein J H., Potvin H, Holman S. A double‐blind, placebo‐controlled clinical trial of fluoxetine in geriatric patients with major depression. The Fluoxetine Collaborative Study Croup. Int Psychogeriatr 1995; 7: 89–104
   PubMedGoogle Scholar
• Uehlinger C, Nil R, Amey B, Baumann P, Dufour H. Citalopram‐lithium combination treatment of elderly depressed patients: a pilot study. Int J Cer Psychiatry 1995; 10: 281–287
   Web of Science ®Google Scholar
• Unützer J, Patrick D L., Diehr P, Simon C, Crembowski D, Katon W. Quality adjusted life years in older adults with depressive symptoms and chronic medical disorders. Int Psychogeriatr 2000a; 12: 15–33
   PubMed Web of Science ®Google Scholar
• Unützer J, Simon C, Belin T R., Datt M, Katon W, Patrick D. Care for depression in HMO patients aged 65 and older. J Am Ceriatr Soc 2000b; 48: 871–878
   Google Scholar
• Üstün T B., Sartorius N. Mental Illness in general health care: an international study. Wiley, Chichester 1995
   Google Scholar
• Van den Hoofdakker R H., Gordijn Kasper S. Sleep deprivation in refractory depression. Refractory Depression: Current Strategies and Future Directions, W A. Nolen, J Zohar, S P. Roose, J D. Amsterdam. Wiley & Sons, Chichester 1994; 129–142
   Google Scholar
• Versiani M, Oggero U, Alterwain P, Capponi R, Dajas F, Heinze‐Martin C, Marquez C A., Poleo M A., Rivero‐Almanzor L E., Rossel L, Schimid‐Burgk W, Udabe R U. A double‐blind comparative trial of moclobemide v. imipramine and placebo in major depressive episodes. Br J Psychiatry 1989, Suppl 6: 72–77
   PubMedGoogle Scholar
• Wassermann E M. Side effects of repetitive transcranial magnetic stimulation. Depress Anxiety 2000; 12: 124–129
   PubMed Web of Science ®Google Scholar
• Wells K B., Hays R D., Burnam M A., Rogers W, Greenfield S, Ware J E., Jr. Detection of depressive disorder for patients receiving prepaid or fee‐for service care. Results from the Medical Outcomes Study. JAMA 1989a; 262: 3298–3302
   PubMed Web of Science ®Google Scholar
• Wells K B., Stewart A, Hays R D., Burnam M A., Rogers W, Daniels M, Berry S, Greenfield S, Ware J E. The functioning and wellbeing of depressed patients. Results from the Medical Outcomes Study. JAMA 1989b; 262: 914–919
   PubMed Web of Science ®Google Scholar
• Wiegand M H., Lauer C J., Schreiber W. Patterns of response to repeated total sleep deprivations in depression. J Affect Disord 2001; 64: 257–260
   PubMed Web of Science ®Google Scholar
• Wijeratne C, Halliday G S., Lyndon R W. The present status of electroconvulsive therapy: a systematic review. Med J Aust 1999; 171: 250–254
   PubMed Web of Science ®Google Scholar
• Wilens T E., Biederman J, Baldessarini R J., Geller B, Schleifer D, Spencer T J., Birmaher B, Goldblatt A. Cardiovascular effects of therapeutic doses of tricyclic antidepressants in children and adolescents. J Am Acad Child Adolesc Psychiatry 1996; 35: 1491–1501
   PubMed Web of Science ®Google Scholar
• Williams J W., Jr, Mulrow C D., Chiquette E, Noel P H., Aguilar C, Cornell J. A systematic review of newer pharmacotherapies for depression in adults: evidence report summary. Ann Intern Med 2000; 132: 743–756
   PubMed Web of Science ®Google Scholar
• Wirz‐Justice A, Van den Hoofdakker R H. Sleep deprivation in depression: what do we know, where do we go?. Biol Psychiatry 1999; 46: 445–453
   PubMed Web of Science ®Google Scholar
• Wirz‐Justice A, Graw P, Krauchi K, Sarrafzadeh A, English J, Arendt J, Sand L. 'Natural' light treatment of seasonal affective disorder. J Affect Disord 1996; 37: 109–120
   PubMed Web of Science ®Google Scholar
• Wisner K L., Perel J M., Findling R L. Antidepressant treatment during breast‐feeding. Am J Psychiatry 1996; 153: 1132–1137
   PubMed Web of Science ®Google Scholar
• Wisner K L., Gelenberg A J., Leonard H, Zarin D, Frank E. Pharmacologic treatment of depression during pregnancy. JAMA 1999; 282: 1264–1269
   PubMed Web of Science ®Google Scholar
• Wisner K L., Zarin D A., Holmboe E S., Appelbaum P S., Gelenberg A J., Leonard H L., Frank E. Risk‐benefit decision making for treatment of depression during pregnancy. Am J Psychiatry 2000; 157: 1933–1940
   PubMed Web of Science ®Google Scholar
• Wittchen H U., Lieb R, Wunderlich U, Schuster P. Comorbidity in primary care: presentation and consequences. J Clin Psychiatry 1999; 60(Suppl 7)29–36
   PubMed Web of Science ®Google Scholar
• Wittchen H U. Epidemiology of affective disorders. Contemporary Psychiatry, H Helmchen, F Henn, H Lauter, N Sartorius. Springer, Heidelberg 2000; Vol. 3: 231–241
   Google Scholar
• Wolkowitz O M., Reus V I. Treatment of depression with antiglucocorticoid drugs. Psychosom Med 1999; 61: 698–711
   PubMed Web of Science ®Google Scholar
• Wolkowitz O M., Reus V I., Keebler A, Nelson N, Friedland M, Brizendine L, Roberts E. Double‐blind treatment of major depression with dehydroepiandrosterone. Am J Psychiatry 1999; 156: 646–649
   PubMed Web of Science ®Google Scholar
• World Health Organization. International Classification of Diseases9th revision. WHO, Geneva 1978
   Google Scholar
• World Health Organization. The ICD‐10 Classification of Mental and Behavioural Disorders ‐ Clinical Descriptions and Diagnostic Guidelines. WHO, Geneva 1992
   Google Scholar
• Wu J C., Bunney W E. The biological basis of an antidepressant response to sleep deprivation and relapse: review and hypothesis. Am J Psychiatry 1990; 147: 14–21
   PubMed Web of Science ®Google Scholar
• Wulsin L R., Vaillant G E., Wells V E. A systematic review of the mortality of depression. Psychosom Med 1999; 61: 6–17
   PubMed Web of Science ®Google Scholar
• Young S N. Use of tryptophan in combination with other antidepressant treatments: a review. J Psychiatry Neurosci 1991; 16: 241–246
   PubMed Web of Science ®Google Scholar
• Young A S., Klap R, Sherbourne C D., Wells K B. The quality of care for depressive and anxiety disorders in the United States. Arch Gen Psychiatry 2001; 58: 55–61
   PubMed Web of Science ®Google Scholar
• Zajecka J. Strategies for the treatment of antidepressant‐related sexual dysfunction. J Clin Psychiatry 2001; 62(Suppl 3)35–43
   PubMed Web of Science ®Google Scholar
• Zesiewicz T A., Gold M, Chari G, Hauser R A. Current issues in depression in Parkinson's disease. Am J Ceriatr Psychiatry 1999; 7: 110–118
   PubMed Web of Science ®Google Scholar
• Zimmer B, Rosen J, Thornton J E., Perel J M., Reynolds C F., 3rd. Adjunctive lithium carbonate in nortriptyline‐resistant elderly depressed patients. J Clin Psychopharmacol 1991; 11: 254–256
   PubMed Web of Science ®Google Scholar
• Zinbarg R E., Barlow D H., Liebowitz M, Street L, Broadhead E, Katon W, Roy‐Byrne P, Lepine J P., Teherani M, Richards J. The DSM‐IV field trial for mixed anxiety‐depression. Am J Psychiatry 1994; 151: 1153–1162
   PubMed Web of Science ®Google Scholar
• Zobel A W., Nickel T, Kunzel H E., Ackl N, Sonntag A, Ising M, Holsboer F. Effects of the high‐affinity corticotropin‐releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J Psychiatr Res 2000; 34: 171–181
   PubMed Web of Science ®Google Scholar
• Zohar J, Kaplan Z, Amsterdam J D. Reserpine augmentation in resistant depression: a review. Advances in Neuropsychiatry and Psychopharmacology, Vol 2: Refractory Depression, J D. Amsterdam. Raven Press, New York 1991; 219–222
   Google Scholar
• Zullino D, Baumann P. Lithium augmentation in depressive patients not responding to selective serotonin reuptake inhibitors. Pharmacopsychiatry 2001; 34: 119–127
   PubMed Web of Science ®Google Scholar